These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 25278330

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
    Housman ST, Keel RA, Crandon JL, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2012 May; 56(5):2576-80. PubMed ID: 22330908
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
    Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP.
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3220-5. PubMed ID: 21518838
    [Abstract] [Full Text] [Related]

  • 7. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH, Crandon JL, Nichols WW, Nicolau DP.
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6913-9. PubMed ID: 25223999
    [Abstract] [Full Text] [Related]

  • 8. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014.
    Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF.
    Antimicrob Agents Chemother; 2016 May; 60(5):2849-57. PubMed ID: 26926635
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
    [Abstract] [Full Text] [Related]

  • 15. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).
    Sader HS, Huband MD, Duncan LR, Flamm RK.
    Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750
    [Abstract] [Full Text] [Related]

  • 16. Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam.
    Khalid A, Lubián AF, Ma L, Lin RCY, Iredell JR.
    Int J Infect Dis; 2020 Apr; 93():252-257. PubMed ID: 32061861
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.
    Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP.
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6137-46. PubMed ID: 22985878
    [Abstract] [Full Text] [Related]

  • 18. Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States.
    Castanheira M, Williams G, Jones RN, Sader HS.
    Microb Drug Resist; 2014 Oct; 20(5):436-40. PubMed ID: 24593056
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
    Sader HS, Castanheira M, Jones RN, Flamm RK.
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):261-265. PubMed ID: 28069328
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z, Kayacan C, Oncul O.
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.